Sevelamer lowering effect on protein-bound uremic toxins in non-dialysis chronic kidney disease patients with hyperphosphatemia: A randomized controlled trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20181018003

Enrollment

Registered

2018-10-18

Start date

2018-10-18

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

&#45

Interventions

Patient will receive sevelamer carbonate (RenvelaÂ®) 800 mg/tablet 1 tablet po tid with meal for 6 months,Patient will receive calcium carbonate 1000 mg/tablet 1 tablet po tid with meal for 6 months

Experimental Drug,Active Comparator Drug

Sevelamer,Calcium carbonate

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients age 18 years old or older. 2. Non-dialysis patients who have eGFR 5.0 mg/dL).

Exclusion criteria

Exclusion criteria: 1. Existing or previous treatment with a phosphate binder within the last 1 month. 2. Recently adjust doses of vitamin D analogue within 3 months. 3. Patients with serum calcium more than 10.2 mg/dL. 4. Pregnancy 5. Patients who are unable to attend follow-up appointments.

Design outcomes

Primary

Measure	Time frame
p-cresol 6 months HPLC	—

Secondary

Measure	Time frame
indoxyl sulfate 6 months HPLC,renal function 6 months GFR (ml/min/1.73m2)	—

Countries

Thailand

Contacts

Public ContactKullaya Takkavatakarn

King Chulalongkorn Memorial Hospital

koykullaya@hotmail.com081-580-7470

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

Sevelamer lowering effect on protein&#45;bound uremic toxins in non&#45;dialysis chronic kidney disease patients with hyperphosphatemia: A randomized controlled trial